Choose your country to see the products for your location
SALSA® MLPA® Probemix P189 CDKL5/ARX/FOXG1 detects copy number variations in the CDKL5, FOXG1, ARX and NTNG1 genes.
Contents: 52 MLPA probes, including 24 probes for CDKL5, 5 probes for ARX, 12 probes for NTNG1 and 2 probes for FOXG1, covering all exons of these genes.
Tissue: genomic DNA isolated from human peripheral whole blood.
Application: CDKL5 deficiency disorder, FOXG1 syndrome, early infantile epileptic encephalopathy 1 (EIEE1) and atypical Rett syndrome.
CE-marked and registered for in vitro diagnostic (IVD) use in selected territories.
The SALSA MLPA Probemix P189 CDKL5/ARX/FOXG1 is an in vitro diagnostic (IVD) or research use only (RUO) semi-quantitative assay for the detection of deletions or duplications in the human CDKL5 and FOXG1 genes, in order to confirm a potential cause for and clinical diagnosis of CDKL5 deficiency disorder and FOXG1 syndrome, respectively. It can also be used for the detection of deletions and duplications in the human ARX and NTNG1 genes, in order to confirm a potential cause for and clinical diagnosis of early infantile epileptic encephalopathy 1 (EIEE1) and atypical Rett syndrome, respectively. This assay is additionally intended for molecular genetic testing of at-risk family members, and is for use with genomic DNA isolated from human peripheral whole blood specimens.
For the full intended purpose, see the product description.
CDKL5 deficiency disorder (also known as early infantile epileptic encephalopathy 2) is a condition characterized by a broad range of clinical symptoms and severity. The primary symptoms include early-onset epilepsy (starting within the first three months of life), generalized hypotonia, psychomotor development disorders, intellectual disability, and cortical vision disorders. CDKL5 deficiency disorder has several features in common with Rett syndrome and was previously described as the early-onset seizure variant of Rett syndrome (see below). However, as other signs and symptoms of CDKL5 deficiency disorder are distinct from those of Rett syndrome, the disorder is nowadays considered a separate clinical entity (Fehr et al. 2013).
CDKL5 deficiency disorder is an X-linked dominantly inherited disorder that is caused by mutations in the CDKL5 gene (Kalscheuer et al. 2003; Scala et al. 2005; Weaving et al. 2004). The prevalence among women is four times higher than in men (Jakimiec et al. 2020), but the course of the disease is usually more severe in male patients. Most cases of CDKL5 deficiency disorder are the result of de novo mutations. It is estimated that ~6.5–10% of the CDKL5 mutations are large deletions or duplications (RettBASE; RettSyndrome.org Variation Database). Mosaicism has been reported for CDKL5 mutations with an overall frequency of 8.8% (Stosser et al. 2018). Large mosaic deletions have also been described (Bartnik et al. 2011; Boutry-Kryza et al. 2014; Mei et al. 2014), but the occurrence rate for mosaic copy number changes has not been determined.
FOXG1 syndrome is a condition characterized by impaired development and structural brain abnormalities. Affected infants are small at birth, and their heads grow more slowly than normal, leading to an unusually small head size (microcephaly) by early childhood. The condition is associated with a particular pattern of brain malformations and affects most aspects of development. Children with the condition typically have severe intellectual disability. FOXG1 syndrome is an autosomal dominant condition that is caused by mutations in the FOXG1 gene (Kortüm et al. 2011; Vegas et al. 2018; Wong et al. 2019). The percentage of FOXG1 syndrome cases explained by large deletions or duplications of FOXG1 varies depending on the phenotype examined, but has been estimated at ~11% (Vegas et al. 2018). FOXG1 syndrome was previously described as the congenital variant of Rett syndrome (see below). However, whereas Rett syndrome is diagnosed almost exclusively in females, FOXG1 syndrome affects both males and females. Because of these differences, FOXG1 syndrome is nowadays considered a distinct disease entity.
Early infantile epileptic encephalopathy (EIEE; also known as developmental and epileptic encephalopathy) is a neurological disorder characterized by seizures. The disorder affects male and female newborns, usually within the first three months of life (most often within the first 10 days) in the form of epileptic seizures. Most infants with the disorder show underdevelopment of part or all of the cerebral hemispheres or structural anomalies. EIEE can be caused by mutations in more than 100 different genes. EIEE1 is an X-linked recessive disease that is caused by mutations in the ARX gene. Males with ARX mutations are often more severely affected than females, but female mutation carriers may also be affected (Kato et al. 2004; Wallerstein et al. 2008). Approximately 3% of identified ARX mutations are large deletions and duplications (Shoubridge et al. 2010).
Rett syndrome is a neurodevelopmental disorder affecting approximately 1:10,000 live female births. Classic Rett syndrome is characterized by a period of normal development during the first 6–18 months of life, followed by loss of already gained skills, such as speech and purposeful hand movement. Additional main features are acquired microcephaly, stereotypic hand movements, impaired locomotion and communication dysfunction (Hagberg et al. 1983). Patients lacking one or more of the major features of Rett syndrome are identified as atypical Rett syndrome cases, which are traditionally subdivided into three distinct clinical subgroups: congenital, early-onset seizure and preserved speech (Hagberg et al. 2002; Hagberg and Skjeldal 1994; Neul et al. 2010; Pini et al. 2016). Most cases of Rett syndrome are caused by de novo mutations in the MECP2 gene (GeneReviews; https://www.ncbi.nlm.nih.gov/books/NBK1497/). However, there is one report that describes a patient with atypical Rett syndrome who presented with early onset of epileptic seizures (not infantile spasms) and a de novo translocation that disrupted the NTNG1 gene on chromosome 1 (Borg et al. 2005). This balanced translocation will not be detected by MLPA as the NTNG1 copy number is not altered. Deletions and duplications of NTNG1 have not been described so far.
Since there are multiple genes involved in the above-described syndromes and since these genes are covered by two different probemixes, i.e. SALSA MLPA Probemix P189 CDKL5/ARX/FOXG1 and SALSA MLPA Probemix P015 MECP2, the table below provides an overview of conditions and genes covered by SALSA MLPA Probemix P015-F2 MECP2 and SALSA MLPA Probemix P189-C2 CDKL5/ARX/FOXG1.
Condition | Genes | Probemix and coverage | Remarks |
---|---|---|---|
Classic Rett syndrome |
MECP2 (4 exons) |
P015-F2: Each exon |
- |
MECP2 duplication syndrome |
MECP2 (4 exons) |
P015-F2: Each exon |
- |
Atypical Rett syndrome |
MECP2 (4 exons) |
P015-F2: Each exon |
- |
NTNG1 (6 exons) |
P189-C2: Each exon P015-F2: Exons 2, 3, 5, 6 |
Exon 3, 5 and 6 probes in P015 have the same ligation site as probes in P189. | |
CDKL5 deficiency disorder |
CDKL5 (21 exons) |
P189-C2: Each exon P015-F2: Exons 3, 6, 9, 10 |
Probes in P015 have the same ligation sites as probes in P189. |
Early infantile epileptic encephalopathy 1 |
ARX (5 exons) |
P189-C2: Each exon P015-F2: Exons 1, 5 |
Probes in P015 have the same ligation sites as probes in P189. |
FOXG1 syndrome |
FOXG1 (1 exon) |
P189-C2: Exon 1 and upstream region |
- |
SALSA MLPA Probemix P189 CDKL5/ARX/FOXG1 is CE-marked for in vitro diagnostic (IVD) use. This assay has also been registered for IVD use in Israel.
This assay is for research use only (RUO) in all other territories.
A general SALSA MLPA Reagent Kit is required for MLPA experiments (to be ordered separately).
The prices above are list prices for direct orders from MRC Holland. Contact us for a quote that takes discounts and additional costs (such as shipping costs) into account. Different prices apply for orders through one of our sales partners; contact your local supplier for a quote.
Inclusion of a positive sample is usually not required, but can be useful for the analysis of your experiments. MRC Holland has very limited access to positive samples and cannot supply such samples. We recommend using positive samples from your own collection. Alternatively, you can use positive samples from an online biorepository, such as the Coriell Institute.
The commercially available positive samples below have been tested with the current (C2) version of this product and have been shown to produce useful results.